Introduction {#S1}
============

The thymus, which produces T-lymphocytes, is known to shrink with aging; thus, many researchers have tried to elucidate the relationship between age and immune system dysfunction by examining losses and changes in circulating T-lymphocytes ([@B1], [@B2]). Nonetheless, decreased thymic output with aging may not affect peripheral T-lymphocytes, because there is a strong homeostatic compensatory mechanism that stimulates independent expansion of mature T-cells from the thymus. However, this expansion will result in a limited T-cell receptor (TCR) repertoire with a decreased ability to adapt to new antigens and infectious agents ([@B3]).

During maturation of T-lymphocytes in the thymus, four TCR genes (α, β, γ, and δ) encode two types of disulfide-linked heterodimers. The majority of TCRs expressed by peripheral T-lymphocytes are composed of α and β chains; however, an alternative TCR comprising γ and δ chains is also expressed by 2--10% of cells ([@B4], [@B5]). T-cell receptor excision circles (TRECs) are stable circular DNA episomes generated during excisional rearrangement of TCR genes during T-lymphocyte division and maturation in the thymus. This process is identical in approximately 70% of αβ-T-cells. As the rate of intracellular degradation of TREC is low and TRECs do not replicate, they remain constant in number, despite being diluted during T-lymphocyte proliferation. Accordingly, these molecules have been used as markers of recent thymic emigrants ([@B5], [@B6]).

Many clinical situations associated with aging have been described as possible causes of impaired thymic function, including changes in growth factor and cytokine expression, low hormone production, and bone marrow loss ([@B7], [@B8]). TREC quantification has been shown in various studies to be more reliable for evaluation of thymic function ([@B9]--[@B16]). A series of observations on TREC dynamics during human immunodeficiency virus (HIV) infection and treatment and in autologous and allogeneic hematopoietic stem cell transplantation (HSCT) confirmed the usefulness of TREC analysis as a quantitative marker for thymic function. Among these studies, some have shown that aging is an important contributor to damaged thymic function through decreased TREC quantification ([@B17]--[@B19]). Other studies have found a relationship between decreased TREC quantification and malignant disease treatment, or increased TREC quantification after highly active antiretroviral therapy (HAART) or HSCT as a sign of thymic function recovery ([@B10], [@B20]--[@B26]).

Accordingly, in this study, we focused on age and thymic function before HSCT in patients who had undergone treatment for malignant hematological diseases and observed their situation after HSCT.

Materials and Methods {#S2}
=====================

Patients and Controls {#S2-1}
---------------------

This study involved patients diagnosed with a hematological malignancy. All patients had an Eastern Cooperative Oncology Group Performance Clinical Status Scale score of 0--1. The patients had not undergone any treatment for infectious diseases at the time of blood collection.

The patients were admitted to the HSCT Program at Amaral Carvalho Hospital, Jaú, São Paulo, between March 2015 and October 2016 (*n* = 111). No history of surgical thymectomy, splenectomy, or positive HIV diagnosis was reported. Among these patients, 39 underwent autologous HSCT (auto-HSCT) and 72 underwent allogeneic HSCT (allo-HSCT). A comparison with a group of healthy blood donors (control group) was performed (*n* = 54; Table [1](#T1){ref-type="table"}).

###### 

Characteristics of patients and healthy individuals.

                       Patients                Healthy individuals     *p*
  -------------------- ----------------------- ----------------------- ---------
  Cohort group, *n*    111 (67.3%)             54 (32.7%)              \<0.001
  Age (range), years   41 (18--60)             40 (19--60)             0.542
  Sex (male/female)    65 (58.6%)/46 (41.4%)   27 (16.4%)/27 (16.4%)   0.301
                                                                       
  Previous diagnosis                                                   
  Allo-HSCT            ALL, 30 (27.1%)         Absent                  
                       AML, 38 (34.2%)         Absent                  
                       MDS, 4 (3.6%)           Absent                  
  Auto-HSCT            HD, 7 (6.3%)            Absent                  
                       NHL, 9 (8.1%)           Absent                  
                       MM, 23 (20.7%)          Absent                  

*ALL, acute lymphocytic leukemia; allo-HSCT, allogeneic HSCT; AML, acute myeloid leukemia; auto-HSCT, autologous HSCT; HD, Hodgkin's disease; HSCT, hematopoietic stem cell transplantation; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-Hodgkin's lymphoma*.

The patients' ages ranged from 18 to 60 years (mean 41 years) and healthy individuals' ages ranged from 19 to 60 years (mean 40 years). The participants were classified into four age groups: 18--24, 25--35, 36--49, and 50--60 years old. Participants were also classified per previous disease diagnosis as follows: acute lymphocytic leukemia (ALL); myeloid diseases for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); lymphomas for non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD); and multiple myeloma (MM).

DNA samples were collected 15--30 days before HSCT, during appointments for clinical evaluation. Volunteer donors' samples were collected from the Blood Transfusion Service for comparison. Venous blood (6 mL) was collected for leukocyte count determination and DNA extraction. The DNA samples were stored at −20°C until use. At the time of assessment, 14.4% of patients had acute leukemias with minimal residual disease, as detected by flow cytometry (AML ≥ 1% and ALL ≥ 0.1% of malignant cells), and 15.3% of patients had MM with partial response (PR) or very good PR, or lymphomas with PR without malignant medullar infiltration. Only three patients (2.7%) had received both chemotherapy and radiotherapy before HSCT. All patients had received their last disease treatment more than 1 month before blood collection, but only 17.1% had received their last treatment more than 6 months previously.

We examined the thymic recovery of these patients and collected new blood samples around the ninth month (270 ± 15 days) post-HSCT. During this period, 6 patients who underwent allo-HSCT died, and another 24 patients did not provide blood samples because they did not attend an appointment during the predefined time around the ninth month. A total of 81 patients were analyzed in this period (30 patients underwent auto-HSCT and 51 underwent allo-HSCT). We noted all the infections that needed hospital treatment or events related to acute and chronic graft-versus-host disease (GvHD) after HSCT. All patients undergoing allo-HSCT were human leukocyte antigen identical matched to donor.

Signal Joint TREC (sjTREC) Quantification {#S2-2}
-----------------------------------------

Genomic DNA was extracted from blood samples using a QIAamp DNA Blood Minikit ([@B27]). Quantification of sjTRECs was performed by real-time quantitative polymerase chain reaction (qPCR) according to the MyTRECKit protocol ([@B28]).

Briefly, the kit was formulated with TaqMan dual-labeled fluorescent probes and a gene expression master mix containing antibody-mediated hot-start DNA polymerase, enhancers, stabilizers, dNTPs, MgCl^2^ cofactor, and a separate ROX reference dye. The reaction was set up with a final volume of 20 µL containing 16 µL of total mix (10 µL of gene expression master mix, 1 µL of primers and probes, 1 µL of reaction enhancer, and 4 µL of nuclease-free water) plus 4 µL DNA sample or 4 µL negative or positive control. The qPCR cycling program was as follows: one cycle at 95°C for 3 min for polymerase activation, followed by 40 cycles at 95°C for 30 s (denaturation) and 60°C for 1 min (annealing/extension) for amplification.

A standard curve was generated using the qPCR instrument (Applied Biosystems QuantStudio 12K Flex; Applied Biosystems, Foster City, CA, USA) by absolute quantification. FAM dye was used as a reporter for sjTREC, and VIC reporter was used for β-actin, an endogenous control. NFQ-MGB was used as a quencher for both genes. ROX dye was applied as a passive reference. The calibration curves were prepared using six different amplification points for both genes as follows: 10^6^, 10^5^, 10^4^, 10^3^, 10^2^, and 25 for the sjTREC standard curve; and 10^7^, 10^6^, 10^5^, 10^4^, 10^3^, and 10^2^ for the β-actin standard curve. Calibrator reactions for standard curves were set up in triplicate, and those for samples and controls were performed in duplicate.

The baseline was kept at cycle 3, and the threshold was fixed at 0.043745 for sjTREC and 0.09886 for β-actin. The slopes were between −3.58 and −3.10, with amplification efficiency values around 96--100% and a correlation coefficient (*R*^2^) greater than 0.99.

Signal joint TREC data were expressed as the number of sjTREC copies per μg of DNA after correlation with the endogenous control gene β-actin.

Statistical Analysis {#S2-3}
--------------------

We used the Student's *t*-test to compare ages of patients and healthy individuals. The sex frequencies were verified through chi-square tests ([@B29]). Previous disease diagnoses were also described in terms of absolute and relative frequencies.

Lymphocyte and sjTREC distribution values were evaluated for both the healthy individuals and the patients groups. sjTREC values were stratified by age group and previous disease diagnosis. Mann--Whitney tests were used for comparisons between two categories, and Kruskal--Wallis tests were used for multiple comparisons, followed by Dunn tests. To observe differences among age groups, we applied ANOVA with Bonferroni correction ([@B29], [@B30]).

Correlations between continuous variables (age and sjTREC copy number) were assessed using Spearman's rank-order correlation.

All sjTREC results were classified as higher or lower values based on the median sjTREC copy number from healthy individuals (606.55 copies). The association between low sjTREC values and the three predefined variables (sex, age, and cohort group) were analyzed by univariate and multivariate logistic regression analyses ([@B30]).

The sjTREC copy numbers were also classified as higher or lower based on the median sjTREC copy number for the post-HSCT patients (166.36 copies). The frequencies among the variables were verified by chi-square tests, Fisher's tests, or the likelihood ratio ([@B29]).

A generalized estimating equation was used to estimate the parameters of a generalized linear model to find possible correlations between the outcomes of the patients before and 9 months after HSCT ([@B30]).

The significance level was set to 0.05 for all tests performed. All *p*-values were based on two-sided tests, and all calculations were performed using IBM-SPSS version 20.0 and the MedCalc statistical software version 17.4 (2017).

Results {#S3}
=======

We enrolled 165 individuals for the present study. They were divided in two groups: healthy individuals (*n* = 54) and patients (*n* = 111). All patients had a previous diagnosis of hematological malignant disease. The two groups were matched by age and sex (Table [1](#T1){ref-type="table"}).

Healthy individuals were compared with patients in relation to lymphocyte count and sjTREC count by lymphocytes (10^6^). We found significant differences between the groups (*p* \< 0.001 for lymphocyte count and *p* = 0.004 for sjTREC count; Table [2](#T2){ref-type="table"}; Figure [1](#F1){ref-type="fig"}).

###### 

Lymphocyte and signal joint TREC (sjTREC) counts.

  Individuals               *n*   Variables                  Minimum   Maximum      Median      25--75 percentile      *p*
  ------------------------- ----- -------------------------- --------- ------------ ----------- ---------------------- ---------
  a\. Healthy individuals   54    Lymphocytes/mm^3^          493       3,822        1,897.5     1,548.0--2,240.0       
  a\. Patients              111   Lymphocytes mm^3^          44        3,88         378         252.25--757.06         \<0.001
  b\. Healthy individuals   54    sjTREC/10^6^ lymphocytes   2,009.9   521,067.3    42,495.4    12,377.93--69,438.76   
  b\. Patients              111   sjTREC/10^6^ lymphocytes   0.32      873,700.28   19,099.71   4,781.55--57,693.64    0.004

![Correlation of lymphocyte count and signal joint TREC (sjTREC) count between healthy individuals and patients.](fimmu-09-01889-g001){#F1}

The ages of the individuals varied from 18 to 60 years old. With increasing age, the number of sjTREC copies/μg DNA decreased for both groups, but the decrease was significant only for the healthy individuals group (*p* \< 0.001; Figure [2](#F2){ref-type="fig"}).

![Correlation between age and signal joint TREC (sjTREC) count.](fimmu-09-01889-g002){#F2}

When the cohort was separated by age group, we found that healthy individuals always had higher sjTREC copy numbers than patients (*p* \< 0.001; Table [3](#T3){ref-type="table"}; Figure [3](#F3){ref-type="fig"}).

###### 

Signal joint TREC copies/μg DNA (according to Figures [3](#F3){ref-type="fig"}--[5](#F5){ref-type="fig"}).

  Figures   Individuals                                  *n*   Minimum   Maximum    Median    25--75 percentile   *p*
  --------- -------------------------------------------- ----- --------- ---------- --------- ------------------- -----------------------------------------
  3         a\. Healthy individuals (8--24 years old)    11    130.77    8,837.3    1,101.0   732.37--1,482.49    
            a\. Patients (8--24 years old)               15    0.01      988.11     98.7      48.236--266.35      \<0.001
            b\. Healthy individuals (25--35 years old)   12    179.81    2,257.75   951.10    292.3--1,388.44     
            b\. Patients (25--35 years old)              22    0.01      1,137.55   56.97     10--203.1           \<0.001
            c\. Healthy individuals (35--49 years old)   14    127.54    1,996.05   589.021   187.25--813.57      
            c\. Patients (35--49 years old)              40    0.01      1,843.38   58.62     28.40--218.58       \<0.001
            d\. Healthy individuals (50--60 years old)   17    28.46     3,015.51   196.05    119.76--604.89      
            d\. Patients (50--60 years old)              34    0.01      548.33     44.98     17.62--105.35       \<0.001
                                                                                                                  
  4         Patients                                     111   0.01      1,843.38   61.59     18.21--163.74       
            Healthy individuals                          54    28.46     8,837.3    606,48    187.25--1,101.0     
            Healthy individuals (50--60 years old)       17    28.46     3,015.51   196.06    119.76--04.89       \<0.001[\*](#tfn1){ref-type="table-fn"}
                                                                                                                  
  5         a\. Healthy individuals                      54    28.46     8,837.3    606.48    187.25--1,101.0     
            b\. Myeloid diseases                         42    0.01      1,843.38   130.5     28.14--303.89       
            c\. ALL                                      30    0.01      988.11     68.04     13.18--165.06       
            d\. Lymphomas                                16    0.01      729.66     61.47     19.84--111.59       
            e\. MM                                       23    0.01      548.33     31.72     18.67--58.62        [\*\*](#tfn2){ref-type="table-fn"}

*\*The differences were significant between patients and healthy individuals (*p* \< 0.001) and between patients and healthy individuals ≥50 years old (*p* \< 0.001)*.

*\*\*The differences were significant between healthy individuals and patients distinguished by their previous hematological diseases (*p* \< 0.001) and also between myeloid diseases and MM subgroups (*p* = 0.002)*.

![Correlation of signal joint TREC (sjTREC) count between healthy individuals and patients by age group.](fimmu-09-01889-g003){#F3}

Patients had significantly lower sjTREC counts than healthy individuals, even in the case of the oldest subgroup of healthy individuals (*p* \< 0.001; Table [3](#T3){ref-type="table"}; Figure [4](#F4){ref-type="fig"}).

![Correlation of signal joint TREC (sjTREC) count between patients and healthy individuals.](fimmu-09-01889-g004){#F4}

Patients were grouped per their previous diagnoses as described in the previous section. Healthy individuals had a greater number of sjTREC copies than any of these patient subgroups (*p* \< 0.001). The myeloid diseases subgroup showed a greater number of sjTREC copies than the MM subgroup (*p* = 0.002; Table [3](#T3){ref-type="table"}; Figure [5](#F5){ref-type="fig"}).

![Correlations of signal joint TREC (sjTREC) count among healthy individuals and patient disease subgroups.](fimmu-09-01889-g005){#F5}

Taking age into consideration, the ALL group was the youngest group (*p* \< 0.001). The myeloid diseases subgroup was younger than the healthy individuals group, and the lymphoma and MM subgroups (*p* \< 0.001). The mean ages for ALL, myeloid diseases, healthy individuals, lymphomas, and MM were 24, 28, 45, 45, and 49 years, respectively (Figure [6](#F6){ref-type="fig"}).

![Correlation of age among patient disease subgroups and healthy individuals.](fimmu-09-01889-g006){#F6}

The median number of sjTREC copies for healthy individuals was 606.55 copies; this value was used to set high and low values for subsequent analyses.

Univariate logistic regression analysis revealed higher odds ratios (ORs) for the three older age subgroups compared with the youngest subgroup (≤24 years old): OR = 3.31 for 25--35 years old (*p* = 0.039), OR 3.00 for 36--49 years old (*p* = 0.032), and OR = 10.07 for 50--60 years old (*p* \< 0.001). Interestingly, the oldest subgroup had an OR that was three times higher for low values of sjTREC than those of the other subgroups.

Multiple logistic regression was applied to all populations studied (*n* = 165). Among the predefined groups, age was an important risk factor; for example, individuals at least 50 years old had an OR of 17.35 \[95% confidence interval (CI) = 3.75--80.21, *p* \< 0.001\] for low values of sjTREC copies. Being in the patient group was considered another independent and important risk factor for low sjTREC copy number \[OR = 17.25 (95% CI = 6.28--47.38), *p* \< 0.001; Table [4](#T4){ref-type="table"}\].

###### 

Univariate and multivariate logistic regression analyses with odds ratios (ORs) for low signal joint TREC (sjTREC) copy numbers (lower than the mean sjTREC copy number of 606.55) based on sex, age, and health condition (*n* = 165).

                        sjTREC value                                                                        
  --------------------- -------------- ------------ ------- ------ ------- --------- ------- ------ ------- ---------
  **Sex**                                                                                                   
  Female                18 (24.7)      55 (75.3)    1.00                             1.00                   
  Male                  17 (18.5)      75 (81.5)    1.44    0.68   3.05    0.336     1.27    0.50   3.25    0.619
  **Age, years**                                                                                            
  18--24                12 (46.2)      14 (53.8)    1.00                             1.00                   
  25--35                7 (20.6)       27 (79.4)    3.31    1.06   10.27   0.039     4.67    1.13   19.27   0.033
  36--49                12 (22.2)      42 (77.8)    3.00    1.10   8.18    0.032     2.84    0.80   10.03   0.105
  50--60                4 (7.8)        47 (92.2)    10.07   2.80   36.20   \<0.001   17.35   3.75   80.21   \<0.001
  **Cohort**                                                                                                
  Healthy individuals   27 (50)        27 (50)      1.00                             1.00                   
  Patients              8 (7.2)        103 (92.8)   12.88   5.26   31.53   \<0.001   17.25   6.28   47.38   \<0.001

Patients were analyzed at two time points relative to HSCT: as candidates for HSCT and 9 months post-HSCT. We also compared patients who underwent auto-HSCT with those who underwent allo-HSCT. There were no differences between the candidates for allo-HSCT and those for auto-HSCT, but both sets had significantly lower sjTREC copy numbers than healthy individuals. Both groups of patients showed good thymic recovery 9 months post-HSCT, i.e., both achieved sjTREC copy numbers similar to those of healthy individuals (Table [5](#T5){ref-type="table"}; Figure [7](#F7){ref-type="fig"}).

###### 

Correlation between types of HSCT (auto- and allo-) and time (pre-HSCT to the ninth month post-HSCT).

  a\. GEE with gamma distribution, identity binding function with first order autoregressive correlation matrix                                                       
  --------------------------------------------------------------------------------------------------------------- ---------- -------- -------- --------- ------------ -----------
  Type of HSCT                                                                                                    18.304              2        \<0.001                
  Time                                                                                                            15.911              1        \<0.001                
  Type of HSCT and time                                                                                           0.007               1        0.932                  
  **b. Bonferroni multiple comparisons**                                                                                                                              
                                                                                                                                                         **95% CI**   
  **Correlation between the variables**                                                                           **Mean**   **SE**   **df**   *p*       **Under**    **Upper**
                                                                                                                                                                      
  Healthy individuals---pre-auto-HSCT patient                                                                     796.06     184.63   1        \<0.001   277.79       1,314.33
  Healthy individuals---post-auto-HSCT patient                                                                    538.32     206.54   1        0.092     −41.45       1,118.1
  Healthy individuals---pre-allo-HSCT patient                                                                     681.96     186.94   1        0.003     157.21       1,206.71
  Healthy individuals---post-allo-HSCT patient                                                                    435        206.03   1        0.347     −143.33      1,013.32
  Pre-auto-HSCT patient---post-auto-HSCT patient                                                                  257.74     90.0     1        0.042     −510.37      −5.11
  Pre-auto-HSCT patient---pre-allo-HSCT patient                                                                   114.1      43.29    1        0.084     −235.63      7.43
  Pre-auto-HSCT patient---post-allo-HSCT patient                                                                  361.06     96.82    1        0.002     −632.85      −89.28
  Post-auto-HSCT patient---pre-allo-HSCT patient                                                                  143.63     102.2    1        0.999     −143.25      430.52
  Post-auto-HSCT patient---post-allo-HSCT patient                                                                 103.33     133.96   1        0.999     −479.36      272.71
  Pre-allo-HSCT patient---post-allo-HSCT patient                                                                  246.96     88.93    1        0.055     −496.60      2.67

*allo-HSCT, allogeneic HSCT; auto-HSCT, autologous HSCT; df, degrees of freedom; GEE, generalized estimating equation; HSCT, hematopoietic stem cell transplantation*.

![Correlation of signal joint TREC (sjTREC) count between healthy individuals and patients (as candidates for HSCT and post-HSCT).](fimmu-09-01889-g007){#F7}

The median number of sjTREC copies from patients after HSCT was determined (166.36 copies), and we compared the characteristics listed in Tables [6](#T6){ref-type="table"} and [7](#T7){ref-type="table"} for both groups of HSCT (auto- and allo-HSCT) and correlated them with poor (lower sjTREC values) or good (higher sjTREC values) thymic recovery. Only episodes of cytomegalovirus (CMV) were related to poor thymic recovery in allo-HSCT patients (*p* = 0.030; Tables [6](#T6){ref-type="table"} and [7](#T7){ref-type="table"}).

###### 

Characteristics of patients 9 months post-autologous hematopoietic stem cell transplantation (HSCT).

  Autologous-HSCT                                                                                                              
  ------------------------------------------ ------------------------ ----------------------------- -------------------------- -------------
  Age groups                                 \<50/≥50 years old       4 (22.2)/14 (77.8)            7 (58.3)/5 (41.7)          0.063
  Sex                                        Male/female              3 (16.7)/15 (83.3)            6 (50)/6 (50)              0.102
  Diagnosis                                  HD/NHL/MM                2 (11.1)/4 (22.2)/12 (66.7)   2 (16.7)/3 (25)/7 (58.3)   0.875
  Treatment for a prior disease              Chemo/chemo plus radio   17 (94.4)/1 (5.6)             11 (91.7)/1 (8.3)          0.999
  Bone marrow status before HSCT             CR/PR or VGPR            11 (61.1)/7 (38.9)            8 (66.7)/4 (33.3)          0.761
  Time between last chemo/radio and HSCT     ≥6 months/\<6 months     1 (5.6)/17 (94.4)             4 (33.3)/8 (66.7)          0.158
  Conditioning regimen (melphalan mg/m^2^)   200/\<200                6 (33.3)/12 (66.7)            5 (41.7)/7 (58.3)          0.712
  Stem cell source                           PBSC                     18 (100)                      12 (100)                   Not applied
  Bacterial infection episodes               Not present/present      9 (50)/9 (50)                 9 (75)/3 (25)              0.260
  CMV infection episodes                     Not present              18 (100)                      12 (100)                   Not applied
  Fungal infection episodes                  Not present/present      18 (100)/0                    11 (91.7)/1 (8.3)          0.400
  Clinical status                            Alive                    18 (100)                      12 (100)                   Not applied
  Total                                      30 (100.0)               18 (100)                      12 (100)                   Not applied

*Chemo, chemotherapy; CMV, cytomegalovirus; CR, complete response; HD, Hodgkin's disease; HSCT, hematological stem cell transplantation; MM, multiple myeloma; NHL, non-Hodgkin's lymphoma; PBSC, peripheral blood stem cell; PR, partial response; radio, radiotherapy; sjTREC, signal joint TREC; VGPR, very good partial response*.

###### 

Characteristics of patients 9 months post-allogeneic hematopoietic stem cell transplantation (HSCT).

  Allogeneic-HSCT                                                                                                                                      
  ---------------------------------------- ------------------------------------------------ ---------------------------- ----------------------------- -------------
  Age groups                               \<50/≥50 years old                               17 (77.3)/5 (22.7)           26 (89.7)/3 (10.3)            0.268
  Sex                                      Male/female                                      11 (50)/11 (50)              12 (41.4)/17 (58.6)           0.540
  Diagnosis                                ALL/AML/MDS                                      9 (40.9)/12 (54.5)/1 (4.5)   12 (41.4)/15 (51.7)/2 (6.9)   0.932
  Treatment for a prior disease            Chemo/chemo plus radio                           21 (95.5)/1 (4.5)            28 (96.6)/1 (3.4)             0.999
  Bone marrow status before HSCT           MRD/active[^a^](#tfn3){ref-type="table-fn"}/CR   7 (31.8)/1 (4.5)/14 (63.6)   6 (20.7)/2 (6.9)/21 (72.4)    0.650
  Time between last chemo/radio and HSCT   ≥6 months/\<6 months                             4 (18.2)/18 (81.8)           5 (17.2)/24 (82.8)            0.999
  Conditioning regimen                     MAC/RIC                                          12 (54.5)/10 (45.5)          23 (79.3)/6 (20.7)            0.059
  Stem cell source                         PBSC/BMSC                                        10 (45.5)/12 (54.5)          11 (37.9)/18 (62.1)           0.589
  Acute-GvHD                               Absent/present                                   10 (45.5)/12 (54.5)          12 (41.4)/17 (58.6)           0.771
  Chronic-GvHD                             Absent/present                                   9 (40.9)/13 (59.1)           15 (51.7)/14 (48.3)           0.443
  Bacterial infection episodes             Not present/present                              7 (31.8)/15 (68.2)           8 (27.6)/21 (72.4)            0.743
  CMV infection episodes                   Not present/present                              1 (4.5)/21 (95.5)            9 (31)/20 (69)                0.030
  Fungal infection episodes                Not present/present                              21 (99.5)/1 (4.5)            25 (86.2)/4 (13.8)            0.375
  Clinical status                          Dead/alive                                       4 (18.2)/18 (81.8)           2 (6.9)/27 (93.1)             0.383
  Total                                    51 (100%)                                        22 (100)                     29 (100)                      Not applied

*ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; chemo, chemotherapy; BMSC, bone marrow stem cell; CMV, cytomegalovirus; CR, complete response; GvHD, graft-versus-host disease; HD, Hodgkin's disease; HSCT, hematological stem cell transplantation; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MRD, minimal residual disease; MM, multiple myeloma; PBSC, peripheral blood stem cell; PR, partial response; radio, radiotherapy; RIC, reduced intensity conditioning; sjTREC, signal joint TREC*.

*^a^Active: three cases of MDS have not received any treatment before HSCT*.

Finally, the patients 9 months post-HSCT who had sjTREC copy numbers greater than the median value observed for healthy individuals (≥606.55 sjTREC copies; *n* = 15) were more likely to suffer from infections, despite many of these patients being less than 50 years old and having shown complete medullary remission before HSCT. In addition, the majority of these patients underwent allo-HSCT and a myeloablative conditioning regimen (Table [8](#T8){ref-type="table"}).

###### 

Characteristics of patients after the ninth month post-HSCT with sjTREC copies/μg DNA higher than the median of sjTREC value observed for healthy individuals (605.55 sjTREC copies/μg DNA).

  Patients with sjTREC ≥ 605.55 copies/μg DNA                                                                             
  --------------------------------------------- ---------------------------------------- -------------------------------- -------------
  Age groups                                    \<50/≥50 years old                       13 (86.7)/2 (13.3)               0.005
  Sex                                           Male/female                              10 (66.7)/5 (33.3)               0.197
  Diagnosis                                     ALL/AML/NHL/MM                           6 (40)/6 (40)/1 (6.7)/2 (13.3)   0.137
  Treatment for a prior disease                 Chemo/chemo plus radio                   15 (100)/0                       Not applied
  Bone marrow status before HSCT                MRD/CR/PR or VGPR                        2 (13.3)/11 (73.3)/2 (13.3)      0.005
  Time between last chemo radio and HSCT        ≥6 months/\<6 months                     4 (26.7)/11 (73.3)               0.071
  Type of HSCT                                  Allo-/auto-                              12 (80)/3 (20.0)                 0.020
  Conditioning regimen                          MAC/RIC/melphalan 200/melphalan \< 200   9 (60)/3 (20)/2 (13.3)/1 (6.7)   0.016
  Stem cell source                              PBSC/BMSC                                6 (40)/9 (60)                    0.439
  Acute-GvHD                                    Allo-HSCT: absent/present/or auto-HSCT   4 (26.7)/8 (53.3)/or 3 (20)      0.247
  Chronic-GvHD                                  Allo-HSCT: absent/present/or auto-HSCT   5 (33.3)/7 (46.7)/or 3 (20)      0.449
  General infection episodes                    Not present/present                      2 (13.3)/13 (86.7)               0.005
  Total                                         Subgroup                                 15 (100)                         Not applied

*ALL, acute lymphocytic leukemia; allo-HSCT, allogeneic HSCT; auto-HSCT, autologous HSCT; AML, acute myeloid leukemia; chemo, chemotherapy; BMSC, bone marrow stem cell; CR, complete response; GvHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; MAC, myeloablative conditioning; MM, multiple myeloma; MRD, minimal residual disease; NHL, non-Hodgkin's lymphoma; PBSC, peripheral blood stem cell; PR, partial response; radio, radiotherapy; RIC, reduced intensity conditioning; sjTREC, signal joint TREC; VGPR, very good partial response*.

Discussion {#S4}
==========

Age-related changes in the immune system may contribute to morbidity and mortality, mainly owing to decreased resistance to infection.

Moreover, the persistence of thymopoiesis and generation of TCR diversity has important implications for immunosenescence. Thymic function gradually decreases after puberty, with progressive changes in the thymic stroma for adipose tissue. However, in recent years, the adult thymus has been shown to remain active late in life and can still generate functional T-cells for the peripheral lymphoid repertoire, even in older individuals (\>60 years old) ([@B3]).

Poor thymic function after HSCT is associated with higher morbidity and mortality. Immediately after HSCT, the thymus shows a temporary decrease in activity, and the circulating post-transplant T-cells derived from both residual mature T-cells present in the donor graft and *de novo* T-cells of the recipient from transplanted donor stem cells provide primary protection against external agents. However, thymic recovery speed is essential for quicker and broader immune responses, and clinical aspects other than age may also affect thymic function after HSCT ([@B10], [@B19], [@B23]--[@B26], [@B31]). Thus, in this study, we examined the relationships among age, patient condition, and thymic function before HSCT and characterized thymic output at the time of HSCT and the patient features associated with the index of thymic recovery.

Some studies have shown that aging is related to a gradual reduction of thymic function, and an inverse relationship between TREC quantity and aging has been reported. Steffens and colleagues studied the impact of aging on thymic output in the first 5 years of life in 121 children, and compared the results with those from 60 healthy individuals aged 23--58 years old. They found inverse correlations between age and coding joint TREC (cjTREC) levels in both groups ([@B32]). Similar results were observed by Geenen and colleagues for sjTRECs in 41 individuals between 1 and 83 years of age ([@B5]). These data were further supported by the results of Naylor and colleagues, who studied sjTRECs in CD4 T-cells in a cohort of individuals ranging from 18 to 90 years of age ([@B3]).

Serana and colleagues evaluated sjTRECs from peripheral blood mononuclear cells (PBMCs) in 37 patients with common variable immunodeficiency and compared the results with those from 78 healthy blood donors. They found a decrease in the number sjTRECs over time, with women showing higher values than men ([@B33]). Moreover, in a group of 172 Korean volunteers aged 16--65 years old, Cho and colleagues found a negative correlation between sjTREC levels and age ([@B14]). Consistent with these findings, our results demonstrated a negative correlation between sjTREC levels and age, although this was more evident in healthy individuals than in patients.

Interestingly, we did not find any differences in median sjTREC numbers between patients who underwent allo-HSCT and those who underwent auto-HSCT. However, the median sjTREC number was higher in patients with myeloid diseases than in patients with MM, and lower in both these groups than in healthy individuals. Thus, malignant hematological diseases and/or prior treatment may have caused similar thymic dysfunction in all patient groups, independently of the type of disease or treatment. In particular, patients with MM showed the lowest median sjTREC and also the highest mean age. Thus, although all groups showed some thymic dysfunction, the dysfunction was more evident in patients with MM, likely owing to the age of individuals in this group.

Thymic atrophy is not only a consequence of aging. Variations in thymic size and thymocyte numbers have also been noted in various physiological or pathological states, including puberty, pregnancy, thymoma, inflammation, exercise, infections, stress, exposure to substances, GvHD, acute respiratory distress, and malnutrition ([@B1]). Many of these processes are transient and reversible, in contrast to thymic involution and aging.

According to Taub and Longo, T-cell recovery after any transitory acquired injury is most likely to be a reflection of thymus responsiveness to increased demand. Similar to the bone marrow, the thymus may respond to stress insults with transient thymic cellularity alterations, which often depend on the type of stimulus and the grade and time of exposure. Under certain circumstances, such as during periods of chronic stress or repeated stimuli, thymic size and function are restored and, in some cases, enhanced responses may be observed. A number of drugs have been shown to induce a transient and reversible involution ([@B7]).

Douek and colleagues studied the relationships between age and sjTRECs/cjTRECs in PBMCs from birth to 73 years of age in healthy individuals, and compared the findings with those from patients who had undergone total thymectomy and patients who were infected with HIV during the early stages of the disease. Notably, the TREC numbers were found to decrease with increasing age, both after thymectomy and during HIV infection, but showed improvement after the introduction of HAART ([@B21]).

Zhang and colleagues measured α1-circles (89-kb TRECs) in a cross-sectional cohort study of 532 healthy individuals ranging in age from infants to 95 years old. They compared 126 HIV-1-infected adults who had never received antiretroviral therapy with 88 age-matched seronegative controls, and compared 42 HIV-1-infected children (0--10 years of age) with 124 age-matched seronegative controls. Individuals infected with HIV in both groups had fewer α1-circles than controls. Moreover, they observed that the number of α1-circles in healthy individuals was relatively stable for the first 10--15 years, decreased sharply at around 20 years of age, and continued to decrease gradually thereafter ([@B34]).

Signal joint TRECs have also been studied in relation to acute cardiac allograft rejection. A negative correlation between sjTREC levels and age was observed in 66 healthy volunteers and in 27 heart transplant recipients. Cardiac transplant recipients showed lower sjTREC levels than age-matched healthy controls ([@B35]). In addition, sjTREC levels were evaluated in 149 samples from individuals who had adverse drug reactions (anaphylaxis, urticaria, eosinophilia, and systemic symptoms) and compared with those from a previous report of 172 healthy individuals. The mean sjTREC level for individuals with altered immunological status was significantly lower than that of healthy individuals. Thus, immunological status was a factor affecting the accuracy of age prediction using sjTREC quantification ([@B18]).

Some studies have reported decreased TREC numbers and poorer thymic function following treatment in patients with hematological diseases. For example, Svaldi and colleagues tested cjTRECs in 25 patients with MM whose samples were collected between the first and second HSCT. They found a correlation between cjTREC levels and aging; patients younger than 50 years old had higher levels of cjTRECs than older patients. Moreover, HSCT resulted in a marked decrease in cjTRECs, followed by recovery 12 months after HSCT ([@B23]). Li and colleagues studied sjTRECs in 88 untreated AML cases and compared them with 38 healthy individuals and with 10 AML cases in remission (AML-CR) as controls. The sjTREC copy numbers in the AML-CR group did not differ from those in the healthy individuals group; however, the sjTREC levels were lower in patients with AML than in healthy individuals, even after adjustment for age. They also found that sjTREC levels were lower in patients in the AML group who were ≥40 years or older, whereas no difference was observed in the same subgroups of healthy individuals ([@B36]).

Sun and colleagues analyzed sjTRECs in 134 patients with diagnoses of HD and NHL aged 18--67 years. Serial analyses of structural changes in thymus showed that hyperplasia occurred in 28.4% of patients within a median of 4 months after chemotherapy. Moreover, sjTREC levels approached a nadir at the end of treatment and rose significantly to reach pretreatment levels 6 months after the end of chemotherapy ([@B37]). In addition, Haining and colleagues studied T-cell homeostasis in 73 children with newly diagnosed ALL who had just started treatment. The median age of the patients in this study was 4 years old (range 1--17 years) and the sample exhibited a bimodal distribution, with a second age peak at 15 years old. This group was compared with a data set from 805 healthy children ranging from 0 to 18 years old. sjTREC levels were measured in CD3^+^ T-cells. At diagnosis, sjTREC levels in patients with ALL were significantly lower than in healthy children, and remained low with respect to age-matched healthy controls during treatment. After 2 years of treatment, 86% of sjTREC values were less than the 10th percentile in healthy controls. The median sjTREC level in children treated for ALL was equivalent to that of 49-year-old controls. These data suggested that thymopoiesis was markedly reduced both in newly diagnosed and chemotherapy-treated patients with ALL, and that it failed to recover at any point during the 2-year treatment course ([@B38]).

Our data showed that thymopoiesis decreased with aging in both healthy individuals and patients. However, sjTREC levels were significantly higher in healthy individuals than in patients, regardless of age. We also found that the median number of sjTREC copies from all patients was significantly lower than that of the oldest healthy individuals (≥50 years old). Overall, these data suggest that thymic function was reduced in patients because of their previous conditions, probably as a consequence of disease status and prior treatments.

Immediately after the HSCT, peripheral T-cell proliferation can be induced to quickly restore the homeostatic pool, because thymic output is limited and slow. We believed that aging and clinical condition prior HSCT resulting from malignant diseases and their treatments would affect thymic output after HSCT. However, independently of the type of HSCT, we could not determine whether some features were related to a worse or a better thymic recovery. The only exception was CMV infection episodes, which were linked to worse thymic recovery in patients who underwent allo-HSCT.

It was particularly notable that most of the patients who showed the best thymic recovery after 9 months post-HSCT were less than 50 years old and presented complete response for disease treatment prior to HSCT.

In the future, a better understanding of the causes of thymic senescence may lead to the identification of approaches to prevent, or at least delay, thymic dysfunction. Even though we have not found a close relationship between impaired thymic function prior to HSCT and worse thymic recovery after HSCT, it is plausible to imagine that patients may have better clinical conditions to face the procedure if they have better thymic function prior to HSCT.
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